SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-012847
Filing Date
2020-11-05
Accepted
2020-11-05 16:10:23
Documents
67
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nbrv-20200930x10q.htm   iXBRL 10-Q 2297228
2 EX-10.1 nbrv-20200930xex10d1.htm EX-10.1 25946
3 EX-31.1 nbrv-20200930xex31d1.htm EX-31.1 10556
4 EX-31.2 nbrv-20200930xex31d2.htm EX-31.2 10586
5 EX-32.1 nbrv-20200930xex32d1.htm EX-32.1 5757
6 EX-32.2 nbrv-20200930xex32d2.htm EX-32.2 5605
7 GRAPHIC nbrv-20200930xex10d1001.jpg GRAPHIC 10408
  Complete submission text file 0001558370-20-012847.txt   8341075

Data Files

Seq Description Document Type Size
8 EX-101.SCH nbrv-20200930.xsd EX-101.SCH 57327
9 EX-101.CAL nbrv-20200930_cal.xml EX-101.CAL 55142
10 EX-101.DEF nbrv-20200930_def.xml EX-101.DEF 274162
11 EX-101.LAB nbrv-20200930_lab.xml EX-101.LAB 516924
12 EX-101.PRE nbrv-20200930_pre.xml EX-101.PRE 453076
13 EXTRACTED XBRL INSTANCE DOCUMENT nbrv-20200930x10q_htm.xml XML 1357761
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37558 | Film No.: 201290520
SIC: 2834 Pharmaceutical Preparations